NCT00005921已完成不适用
An Open, Serial-Panel, Multiple-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of L-743,872 in Patients With Candida Esophagitis
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
研究概览
简要总结
The purpose of this study is to see if it is safe to give L-743,872 to men with candidal esophagitis, an AIDS-related yeast infection in the esophagus.
详细描述
In this open-label study, patients receive intravenous L-743,872 every 24 hours at one of three dose levels for 14 days. Post-study safety evaluations continue for 4 weeks after the final dose. Pharmacokinetics and safety measurements are taken throughout the 6-week study.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •You may be eligible for this study if you:
- •Are an 18- to 65-year-old man with candidal esophagitis.
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With FluconazoleCandidiasis, OralHIV InfectionsNCT00005920Merck Sharp & Dohme LLC70
已完成
1 期
Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female SubjectsHealthyNCT01737996Boehringer Ingelheim32
终止
1 期
A Safety Study of LY3462817 and LY3509754 in Participants With PsoriasisPsoriasisNCT04152382Eli Lilly and Company30
已完成
3 期
A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell LymphomaPersistent or Recurrent Cutaneous T-Cell LymphomaNCT01871727Eisai Inc.112
进行中（未招募）
4 期
Canadian Continuation of Roll-over Study in Patients With Endogenous Cushing's SyndromeEndogenous Cushing SyndromeNCT06131580Centre hospitalier de l'Université de Montréal (CHUM)7